Search

Displaying results 471 - 480 of 2817 in total
  1. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]

  2. Drug

    Udenafil

    go.drugbank.com/drugs/DB06267
    Approved

    It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [L48216] α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization of lymphocytes and thus contributing

  4. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP).

  5. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. It is a taurine conjugate of ursodeoxycholic acid with comparable therapeutic effi...

  6. Drug

    Theophylline

    go.drugbank.com/drugs/DB00277
    ApprovedInvestigational

    Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  7. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  8. Drug

    Buprenorphine

    go.drugbank.com/drugs/DB00921
    ApprovedIllicitInvestigationalVet approved

    [L46571] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: TRANSTEC PRO 35MCG/H20MG/P, TRANSTEC PRO 70MCG/H40MG/P
  9. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    Hexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®.

  10. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985] … In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors